Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

GF092

Sigma-Aldrich

TRAIL Protein, Recombinant human

Human TRAIL (TNF-Related Apoptosis Inducing Ligand), also called APO2 Ligand, is a cytotoxic protein which activates rapid apoptosis in tumor cells, but not in normal cells.

Sinónimos:

Apo2 Ligand

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Código UNSPSC:
12352202
eCl@ss:
32160405
NACRES:
NA.75

origen biológico

human

Nivel de calidad

recombinante

expressed in E. coli

Ensayo

>98% (SDS-PAGE and HPLC)

Formulario

solid

mol peso

19.6 kDa

fabricante / nombre comercial

Chemicon®

técnicas

cell culture | mammalian: suitable

impurezas

<0.1 ng/μg Endotoxin (of TRAIL/Apo2L; 1EU/μg)

entrada

sample type hematopoietic stem cell(s)

idoneidad

suitable for molecular biology

Nº de acceso NCBI

Nº de acceso UniProt

Condiciones de envío

dry ice

Información sobre el gen

human ... TNFSF10(8743)

Descripción general

Research area: CancerTNF-Related Apoptosis-Inducing Ligand (TRAIL) is a cytotoxic and type II membrane protein. It belongs to the tumor necrosis factor (TNF) superfamily. TRAIL is expressed by the cells of the immune system including natural killer cells, macrophages, T cells, and dendritic cells. TRAIL Protein, Recombinant human is a 19.6 kDa protein

Aplicación

TRAIL Protein, Recombinant human has been used as anapoptosis inducer: to extract cell-free DNA (cfDNA) from various cell linesalong with BV6 to study its anticancer effects in breast cancer cell lines, tostudy its effects of ethanol-induced interferon expression on TRAIL release in neurons

Acciones bioquímicas o fisiológicas

TNF-Related Apoptosis-Inducing Ligand (TRAIL) promotes rapid apoptosis in tumor cells while sparing normal cells. Thisproperty of TRAIL makes it an important biotherapeutic agent in cancer therapy.It induces apoptosis by binding to two death signaling receptors, DR4 and DR5expressed on cell membranes.

Forma física

Sterile filtered, then lyophilized from 0.3 mg/mL in 10mM Sodium Phosphate + 110 mM NaCl.

Almacenamiento y estabilidad

The lyophilized protein may be stored at room temperature for a few weeks, but is best stored at -20°C. After a quick spin, reconstitute in sterile water to a concentration of 0.5-1.0 mg/mL. This solution can be diluted into other buffered solutions and stored at 4ºC for 1 week or -20ºC for future use. Reconstituted GF092 should be stored in undiluted aliquots at -20°C for up to 6 months from date of receipt. Avoid repeated freeze/thaw cycles.

Información legal

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Cláusula de descargo de responsabilidad

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Frank A E Kruyt
Cancer letters, 263(1), 14-25 (2008-03-11)
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors are promising targets for the selective eradication of tumor cells while sparing normal cells. Currently, both recombinant TRAIL proteins and TRAIL receptor agonistic antibodies are being tested in the clinic, showing encouraging antitumor
The clinical trail of TRAIL
Duiker E W, et al.
European Journal of Cancer, 42(14), 2233-2240 (2006)
Hong Wang et al.
Molecular cancer therapeutics, 19(12), 2585-2597 (2020-11-18)
Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role
Sahar Rafat et al.
Biology, 11(11) (2022-11-12)
Cancer is the utmost common disease-causing death worldwide, characterized by uncontrollable cell division with the potential of metastasis. Overexpression of the Inhibitors of Apoptosis proteins (IAPs) and autophagy correlates with tumorigenesis, therapeutic resistance, and reoccurrence after anticancer therapies. This study
Brad A Davidson et al.
Communications biology, 7(1), 441-441 (2024-04-11)
Clinical circulating cell-free DNA (cfDNA) testing is now routine, however test accuracy remains limited. By understanding the life-cycle of cfDNA, we might identify opportunities to increase test performance. Here, we profile cfDNA release across a 24-cell line panel and utilize

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico